| 前列腺癌与前列腺增生Ki-67／PCNA mRNA特异性表达比值的研究 |
| |
| 引用本文： | 钟惟德,张阳德,毕学成,叶永康,韩兆冬,戴奇山,梁宇翔,蔡岳斌,何慧婵. 前列腺癌与前列腺增生Ki-67／PCNA mRNA特异性表达比值的研究[J]. 中国医学文摘(检验与临床), 2009, 0(1): 28-31 |
| |
| 作者姓名： | 钟惟德 张阳德 毕学成 叶永康 韩兆冬 戴奇山 梁宇翔 蔡岳斌 何慧婵 |
| |
| 作者单位： | [1]广州市第一人民医院泌尿外科,510180 [2]中南大学湘雅医院卫生部纳米生物技术重建实验室,510180 |
| |
| 基金项目： | 国家自然科学基金资助项目（30872960）;国家高科技863资助项目（2006AA02A245）;广东省自然科学基金资助项目（04003650） |
| |
| 摘 要： | 目的以实时荧光定量RT-PCR技术研究良性前列腺增生（BPH）与前列腺癌（PCa）组织标本Ki-67蛋白和组织核增殖抗原（PCNA）mRNA的比值，探讨此比值在PCa诊断中的特异性意义。方法通过实时荧光定量RT-PCR检测63例PCa和37例BPH前列腺组织Ki-67／PCNA mRNA的表达，比较其在PCa与BPH组织中定量的差异。结果BPH与PCa组织Ki-67／PC—NA mRNA的定量表达值分别为2．264±0．460与5．905±0．780，差异有统计学意义（P〈0．05）。结论实时荧光定量RT-PCR检测Ki-67／PCNA mRNA为PCa的诊断提供了可靠的辅助指标。
|
| 关 键 词： | 前列腺肿瘤 基因表达 实时荧光定量RT-PCR Ki-67／PCNA |
Ratio of Ki-67/PCNA mRNA and its application in the diagnosis of BHP and prostate cancer |
| |
| ZHONG Wei-de,ZHANG Yang-de,BI Xue-cheng,YE Yong-kang,HAN Zhao-dong,DAI Qi-shan,LIANG Yu-xiang,CAI Yue-bin,HE Hui-chan. Ratio of Ki-67/PCNA mRNA and its application in the diagnosis of BHP and prostate cancer[J]. , 2009, 0(1): 28-31 |
| |
| Authors: | ZHONG Wei-de ZHANG Yang-de BI Xue-cheng YE Yong-kang HAN Zhao-dong DAI Qi-shan LIANG Yu-xiang CAI Yue-bin HE Hui-chan |
| |
| Affiliation: | . (Department of Urology, the First People＇s Hospital of Guangzhou, Guangzhou 510180, China) |
| |
| Abstract: | Objective To study the ratio of Ki-67/PCNA mRNA and explore its application in the diagnosis of BPH and PCa. Methods A sensitive, real-time quantitative PCR assay was used to compare the expression difference of Ki-67/PCNA mRNA in BPH, PCa prostate tissue. Totally 63 samples of PCa and 37 BHP were studied. Results The ratio of Ki-67/PCNA mRNA in BPH and PCa prostate tissue is 2. 264±0. 460 and 5. 905±0. 780 respectively （P〈0. 05）. Conclusions The detection result of Ki-67/PCNA mRNA expression by QRT-PCR may provide reliable diagnostic information for differential diagnosis of PCa. |
| |
| Keywords: | Prostatic neoplasms Gene expression Real-time quantitative RT-PCR Ki-67/PCNA |
| 本文献已被 维普 等数据库收录！ |
